Health Canada Approves Nextstellis for Contraceptive Use

Health Canada has issued a Notice of Compliance for Nextstellis, approving the drug (estetrol monohydrate and drospirenone) for pregnancy prevention. The decision confirms the drug's consistent manufacturing quality and manageable safety profile through appropriate labeling and monitoring. This approval expands contraceptive options available in Canada.